Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences Announces Expected Record Date for Spin-Off [Yahoo! Finance]
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences (NASDAQ:RNA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.